- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
New ANDA Cases
Summer 2014
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Torrent Pharms. Ltd. v. Merck Frosst Canada & Co., IPR2014-00559 (PTAB) |
Apr. 1, 2014 |
N/A |
Daliresp® (roflumilast tablets) |
6,448,274 |
Bayer Pharma AG v. Par Pharm., Inc., 14-2065 (D.N.J.) |
Apr. 2, 2014 |
Hon. Jose L. Linares |
Staxyn® (vardenafil hydrochloride tablets) |
8,613,950 |
Noven Pharms., Inc. v. Novartis AG, IPR2014-00549 (PTAB) |
Apr. 2, 2014 |
N/A |
Exelon® (rivastigmine extended-release film) |
6,316,023 |
Noven Pharms., Inc. v. Novartis AG, IPR2014-00550 (PTAB) |
Apr. 2, 2014 |
N/A |
Exelon® (rivastigmine extended-release film) |
6,335,031 |
Purdue Pharma L.P. v. Teva Pharms. USA, Inc., 14-2357 (S.D.N.Y.) |
Apr. 3, 2014 |
Hon. Sidney H. Stein |
OxyContin® (oxycodone hydrochloride extended-release tablets) |
6,488,963 |
Otsuka Pharm. Co., Ltd. v. Hetero USA Inc., 14-0421 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Samsca® (tolvaptan tablets) |
8,501,730 |
Reckitt Benckiser Pharms. Inc. v. Par Pharm., Inc., 14-0422 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832 |
Sanofi v. Alembic Pharms. Ltd., 14-0424 (D. Del.) |
Apr. 4, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Helsinn Healthcare S.A. v. Cipla Ltd., 14-0427 (D. Del.) |
Apr. 7, 2014 |
Hon. Gregory M. Sleet |
Aloxi® (palonosetron hydrochloride intravenous solution) |
8,598,218 |
Mallinckrodt LLC v. Metrics, Inc., 14-2219 (D.N.J.) |
Apr. 7, 2014 |
Hon. Susan D. Wigenton |
Pennsaid® (diclofenac sodium topical solution) |
8,217,078 |
Kowa Co., Ltd. v. Aurobindo Pharma Ltd., 14-2497 (S.D.N.Y.) |
Apr. 9, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Aurobindo Pharma Ltd., 14-2290 (D.N.J.) |
Apr. 10, 2014 |
Hon. Peter G. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Novartis Pharms. Corp. v. Dr. Reddy's Labs., Ltd., 14-2329 (D.N.J.) |
Apr. 10, 2014 |
Hon. Claire C. Cecchi |
Gleevec® (imatinib mesylate capsules) |
RE43,932 |
The Medicines Co. v. Aurobindo Pharma Ltd., 14-2367 (D.N.J.) |
Apr. 11, 2014 |
Hon. Peter G. Sheridan |
Angiomax® (bivalirudin for injection) |
7,582,727 |
Glenmark Generics Ltd. v. Sanofi-Aventis U.S. LLC, 14-2374 (D.N.J.) |
Apr. 11, 2014 |
Hon. Stanley R. Chesler |
DDAVP® (desmopressin acetate tablets) |
7,022,340 |
Kowa Co., Ltd. v. Mylan, Inc., 14-2647 (S.D.N.Y.) |
Apr. 14, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Eli Lilly and Co. v. Apotex Corp., 14-0586 (S.D. Ind.) |
Apr. 16, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00651, -00652 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,723,340 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00653, -00654 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,340,475 |
Endo Pharms., Inc. v. Depomed, Inc., IPR2014-00655, -00656 (PTAB) |
Apr. 17, 2014 |
N/A |
Gralise® (gabapentin tablets) |
6,635,280 |
Kowa Co., Ltd. v. Mylan, Inc., 14-0504 (W.D. Pa.) |
Apr. 17, 2014 |
Hon. Arthur J. Schwab |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Amneal Pharms., LLC, 14-2758 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Orient Pharma Co., Ltd., 14-2759 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 14-2760 (S.D.N.Y.) |
Apr. 17, 2014 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Hospira, Inc. v. Aurobindo Pharma Ltd., 14-0486 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Ben Venue Labs., Inc., 14-0487 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Actavis US Holding LLC, 14-0488 (D. Del.) |
Apr 18, 2014 |
Hon. Gregory M. Sleet |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Akorn, Inc., 14-2811 (N.D. Ill.) |
Apr 18, 2014 |
Hon. Robert M. Dow, Jr. |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Hospira, Inc. v. Intas Pharms. Ltd., 14-0336 (M.D.N.C.) |
Apr 18, 2014 |
Hon. N. C. Tilley, Jr. |
Precedex® (dexmedetomidine hydrochloride injection) |
6,716,867 |
Kowa Co., Ltd. v. Amneal Pharms., LLC, 14-2488 (D.N.J.) |
Apr. 18, 2014 |
Hon. Peter G. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Forest Labs., Inc. v. Amneal Pharms. LLC, 14-0508 (D. Del.) |
Apr. 21, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
5,061,703 |
Amarin Pharma, Inc. v. Apotex, Inc., 14-2550 (D.N.J.) |
Apr. 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Amarin Pharma, Inc. v. Roxane Labs., Inc., 14-2551 (D.N.J.) |
Apr. 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Kowa Co., Ltd. v. Zydus Pharms. (USA) Inc., 14-2552 (D.N.J.) |
Apr. 22, 2014 |
Hon. Peter J. Sheridan |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Hyperion Therapeutics, Inc. v. Par Pharm., Inc., 14-0384 (E.D. Tex.) |
Apr. 23, 2014 |
Hon. Rodney Gilstrap |
Ravicti® (glycerol phenylbutyrate oral liquid) |
8,404,215 |
AbbVie, Inc. v. Hetero USA Inc., 14-0543 (D. Del.) |
Apr. 24, 2014 |
Hon. Richard G. Andrews |
Norvir® (ritonavir tablets) |
8,470,347 |
Amarin Pharma, Inc. v. Apotex, Inc. 14-2958 (N.D. Ill.) |
Apr. 24, 2014 |
Hon. James F. Holderman |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Dow Pharm. Sciences, Inc. v. Actavis, Inc., 14-2661 (D.N.J.) |
Apr. 25, 2014 |
Hon. Stanley R. Chesler |
Acanya® (clindamycin phosphate / benzoyl peroxide gel) |
8,663,699 |
The Medicines Co. v. Exela Pharma Sciences, LLC, 14-0058 (W.D.N.C.) |
Apr. 25, 2014 |
Hon. Richard Voorhees |
Angiomax® (bivalirudin for injection) |
7,582,727 |
Amarin Pharma, Inc. v. Roxane Labs., Inc., 14-0901 (N.D. Ohio) |
Apr. 25, 2014 |
Hon. Christopher A. Boyko |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Otsuka Pharm. Co., Ltd. v. Amneal Pharms., LLC, 14-2700 (D.N.J.) |
Apr. 28, 2014 |
Hon. Mary L. Cooper |
Abilify® (aripiprazole oral solution) |
8,642,600 |
Cephalon, Inc. v. Uman Pharma Inc., 14-0568 (D. Del.) |
Apr. 30, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder per vial for infusion) |
8,445,524 |
Celgene Corp. v. Fresenius Kabi USA, LLC, 14-0571 (D. Del.) |
Apr. 30, 2014 |
Hon. Richard G. Andrews |
Istodax® (romidepsin for injection) |
7,608,280 |
Amarin Pharma, Inc. v. Dr. Reddy's Labs., Inc., 14-2760 (D.N.J.) |
Apr. 30, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Cephalon, Inc. v. Uman Pharma Inc., 14-3114 (S.D.N.Y.) |
May 1, 2014 |
Hon. Thomas P. Griesa |
Treanda® (bendamustine hydrochloride powder per vial for infusion) |
8,445,524 |
Senju Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 14-0579 (D. Del.) |
May 2, 2014 |
Hon. Sue L. Robinson |
Zymaxid® (gatifloxacin) ophthalmic solution) |
6,333,045 |
Impax Labs., Inc. v. Meda Pharms., Inc., IPR2014-00731 (PTAB) |
May 7, 2014 |
N/A |
Astepro® (azelastine hydrochloride nasal spray) |
8,071,073 |
Kowa Co., Ltd. v. Orient Pharma Co., Ltd., 14-3336 (N.D. Ill.) |
May 7, 2014 |
Hon. Matthew F. Kennelly |
Livalo® (pitavastatin calcium tablets) |
5,856,336 |
Cephalon, Inc. v. Innopharma, Inc., 14-0590 (D. Del.) |
May 9, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder for IV) |
8,609,863 |
Otsuka Pharm. Co., Ltd. v. Almebic Pharms. Ltd., 14-2982 (D.N.J.) |
May 9, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Alza Corp. v. Mylan Pharms. Inc., 14-0594 (D. Del.) |
May 12, 2014 |
Hon. Richard G. Andrews |
Concerta® (methylphenidate hydrochloride) |
8,163,798 |
Alza Corp. v. Mylan Pharms. Inc., 14-0085 (N.D.W.V.) |
May 15, 2014 |
Hon. Irene M. Keeley |
Concerta® (methylphenidate hydrochloride) |
8,163,798 |
Celgene Corp. v. Natco Pharma Ltd., 14-3126 (D.N.J.) |
May 15, 2014 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
8,530,498 |
Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 14-3168 (D.N.J.) |
May 16, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Dr. Reddy's Labs., Inc. v. Purdue Pharm. Products L.P., 14-3230 (D.N.J.) |
May 20, 2014 |
Hon. Jose L. Linares |
Intermezzo® (zolpidem tartrate sublingual tablets) |
7,658,945 |
Jazz Pharms., Inc. v. Amneal Pharms., LLC, 14-3235 (D.N.J.) |
May 20, 2014 |
Hon. Esther Salas |
Xyrem® (sodium oxybate oral solution) |
8,589,182 |
Alcon Research, Ltd. v. Watson Labs., Inc., 14-0647 (D. Del.) |
May 20, 2014 |
Hon. Sue L. Robinson |
Travatan Z® (travoprost ophthalmic solution) |
8,268,299 |
Amarin Pharma, Inc. v. Watson Labs., Inc., 14-3259 (D.N.J.) |
May 21, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Allergan, Inc. v. Actavis PLC, 14-0638 (E.D. Tex.) |
May 22, 2014 |
Hon. Rodney Gilstrap |
Restasis® (cyclosporine ophthalmic emulsion 0.05%) |
8,633,162 |
Otsuka Pharm. Co., Ltd. v. Aurobindo Pharma Ltd., 14-3306 (D.N.J.) |
May 23, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
AstraZeneca AB v. Aurobindo Pharma Ltd., 14-0664 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Glenmark Generics Ltd., 14-0665 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Watson Labs., Inc., 14-0666 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Wockhardt BIO AG, 14-0667 (D. Del.) |
May 23, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
RE44,186 |
AstraZeneca AB v. Watson Labs., Inc., 14-3428 (D.N.J.) |
May 24, 2014 |
Hon. Mary L. Cooper |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Cephalon, Inc. v. Breckenridge Pharm., Inc., 14-0671 (D. Del.) |
May 27, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride powder for IV) |
8,445,524 |
Torrent Pharms. Ltd. v. Novartis AG, IPR2014-00784 (PTAB) |
May 27, 2014 |
N/A |
Gilenya® (fingolimod capsules) |
8,324,283 |
Pack Pharms. LLC v. Alza Corp., IPR2014-00868 (PTAB) |
May 30, 2014 |
N/A |
Glucotrol® XL (glipizide extended release tablets) |
RE44,459 |
Forest Labs., Inc. v. Ranbaxy, Inc., 14-0686 (D. Del.) |
May 30, 2014 |
Hon. Leonard P. Start |
Namenda XR® (memantine hydrochloride extended-release capsules) |
8,168,209 |
Otsuka Pharm. Co., Ltd. v. Wockhardt Bio AG, 14-3445 (D.N.J.) |
May 30, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,642,760 |
Apotex Corp. v. ViiV Healthcare UK Ltd., IPR2014-00876 (PTAB) |
June 2, 2014 |
N/A |
Epzicom® (abacavir sulfate / lamivudine tablets) Trizivir® (abacavir sulfate / lamivudine / zidovudine tablets) |
6,417,191 |
AstraZeneca AB v. Sun Pharma Global FZE, 14-0694 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 7,951 |
AstraZeneca AB v. Teva Pharm. USA, Inc., 14-0695 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
AstraZeneca AB v. Mylan Pharms., Inc., 14-0696 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Amneal Pharms. LLC, 14-0697 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Apotex Corp., 14-0698 (D. Del.) |
June 2, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Gilead Sciences, Inc. v. Mylan Inc., 14-3928 (S.D.N.Y.) |
June 2, 2014 |
Hon. Richard J. Sullivan |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245 |
AstraZeneca Pharms. LP v. Sandoz Inc., 14-3547 (D.N.J.) |
June 3, 2014 |
Hon. Renee Marie Bumb |
Faslodex® (fulvestrant injection) |
6,774,122 |
AstraZeneca AB v. Sun Pharma Global FZE, 14-3552 (D.N.J.) |
June 3, 2014 |
Hon. Mary L. Cooper |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
AstraZeneca AB v. Mylan Pharms., Inc., 14-0094 (N.D.W.V.) |
June 3, 2014 |
Hon. Irene M. Keeley |
Onglyza® (saxagliptin hydrochloride tablets) Kombiglyze XR™ (saxagliptin hydrochloride / metformin hydrochloride extended-release tablets) |
RE44,186 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00885 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,922,695 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00886 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,935,946 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00887 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
5,977,089 |
Mylan Pharms. Inc. v. Gilead Sciences, Inc., IPR2014-00888 (PTAB) |
June 4, 2014 |
N/A |
Stribild® (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate tablets) |
6,043,230 |
Helsinn Healthcare S.A. v. Mylan, Inc., 14-0709 (D. Del.) |
June 4, 2014 |
Hon. Gregory M. Sleet |
Aloxi® (palonosetron hydrochloride intravenous solution) |
7,947,724 |
Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 14-3558 (D.N.J.) |
June 4, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Bristol-Myers Squibb Co. v. Aurobindo Pharma U.S.A., Inc., 14-3585 (D.N.J.) |
June 4, 2014 |
Hon. Mary L. Cooper |
Reyataz® (atazanavir sulfate capsules) |
6,087,383 |
AstraZeneca AB v. Apotex Corp., 14-61309 (S.D. Fla.) |
June 4, 2014 |
Hon. William P. Dimitrouleas |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Teva Women's Health v. Lupin Ltd., 14-4055 (S.D.N.Y.) |
June 4, 2014 |
Hon. Lorna G. Schofield |
Quartette® (levonorgestrel / ethinyl estradiol tablets) |
8,415,332 |
Warner Chilcott Co., LLC v. Amneal Pharms. LLC, 14-0718 (D. Del.) |
June 6, 2014 |
Hon. Gregory M. Sleet |
Enablex® (darifenacin hydrobromide extended-release tablets) |
6,106,864 |
Warner Chilcott Co., LLC v. Lupin Atlantis Holdings S.A., 14-1827 (D. Md.) |
June 6, 2014 |
Hon. Roger W. Titus |
Minastrin® 24 Fe (ethinyl estradiol / norethindrone acetate tablets) |
6,667,050 |
Cipher Pharms. Inc. v. Actavis Labs. FL, Inc., 14-3653 (D.N.J.) |
June 6, 2014 |
Hon. Joseph E. Irenas |
Absorica® (isotretinoin capsules) |
7,435,427 |
Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 14-3251 (E.D. Pa.) |
June 6, 2014 |
Hon. Nitza I. Quinones Alejandro |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Gilead Sciences, Inc. v. Mylan Inc., 14-0099 (N.D.W.V.) |
June 9, 2014 |
Hon. Irene M. Keeley |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245 |
Vivus, Inc. v. Actavis Labs. FL, Inc., 14-3786 (D.N.J.) |
June 12, 2014 |
Hon. Faith S. Hochberg |
Qsymia® (phentermine / topiramate extended-release capsules) |
7,056,890 |
Alza Corp. v. Sandoz Inc., 14-0744 (D. Del.) |
June 13, 2014 |
Hon. Richard G. Andrews |
Concerta® (methylphenidate hydrochloride extended-release tablets) |
8,163,798 |
Vanda Pharms. Inc. v. Roxane Labs., Inc., 14-0757 (D. Del.) |
June 16, 2014 |
Hon. Gregory M. Sleet |
Fanapt® (iloperidone tablets) |
8,586,610 |
Alza Corp. v. Sandoz Inc., 14-3838 (D.N.J.) |
June 13, 2014 |
Hon. Joseph E. Irenas |
Concerta® (methylphenidate hydrochloride extended-release tablets) |
8,163,798 |
Novartis AG v. Glenmark Pharms., Ltd., 14-0771 (D. Del.) |
June 18, 2014 |
Hon. Leonard P. Stark |
Myfortic® (mycophenolate sodium delayed-release tablets) |
6,025,391 |
Merck Sharp & Dohme Corp. v. Fresenius Kabi USA, LLC, 14-3917 (D.N.J.) |
June 18, 2014 |
Hon. Peter G. Sheridan |
Emend® (fosaprepitant dimeglumine for injection) |
5,691,336 |
Amarin Pharma, Inc. v. Andrx Labs., LLC, 14-3924 (D.N.J.) |
June 18, 2014 |
Hon. Mary L. Cooper |
Vascepa® (icosapent ethyl capsules) |
8,293,728 |
Spectrum Pharms., Inc. v. Ben Venue Labs., Inc., 14-0980 (D. Nev.) |
June 18, 2014 |
Hon. Gloria M. Navarro |
Fusilev® (levoleucovorin calcium for injection) |
6,500,829 |
Cephalon, Inc. v. Actavis Labs. FL, Inc., 14-0776 (D. Del.) |
June 19, 2014 |
Hon. Sue L. Robinson |
Fentora® (fentanyl buccal tablets) |
6,200,604 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0777 (D. Del.) |
June 19, 2014 |
Hon. Richard G. Andrews |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
Allos Therapeutics, Inc. v. Teva Pharms. USA, Inc., 14-0778 (D. Del.) |
June 19, 2014 |
Hon. Richard G. Andrews |
Folotyn® (pralatrexate for injection) |
6,028,071 |
Pfizer Inc. v. CFT Pharms. LLC, 14-0781 (D. Del.) |
June 19, 2014 |
Hon. Sue L. Robinson |
Tygacil® (tigecycline injectable IV infusion) |
7,879,828 |
Cephalon, Inc. v. Actavis Labs. FL, Inc., 14-3936 (D.N.J.) |
June 19, 2014 |
Hon. Stanley R. Chesler |
Fentora® (fentanyl buccal tablets) |
6,200,604 |
Janssen Pharms., Inc. v. Roxane Labs., Inc., 14-3941 (D.N.J.) |
June 19, 2014 |
Hon. Claire C. Cecchi |
Nucynta® (tapentadol hydrochloride extended-release tablets) |
RE39,593 |
Teva Women's Health, Inc. v. Watson Labs., Inc., 14-4439 (S.D.N.Y.) |
June 19, 2014 |
Hon. John G. Koeltl |
Quartette® (levonorgestrel / ethinyl estradiol tablets) |
8,415,332 |
Otsuka Pharm. Co., Ltd. v. Par Pharm., Inc., 14-0789 (D. Del.) |
June 20, 2014 |
Hon. Richard G. Andrews |
Samsca® (tolvaptan tablets) |
5,753,677 |
Avanir Pharms., Inc. v. Ranbaxy Labs. Ltd., 14-0792 (D. Del.) |
June 20, 2014 |
Hon. Leonard P. Stark |
Nuedexta® (dextromethorphan hydrobromide / quinidine sulfate capsules) |
7,659,282 |
Senju Pharm. Co., Ltd. v. Metrics, Inc., 14-3962 (D.N.J.) |
June 20, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution) |
8,129,431 |
Otsuka Pharm. Co., Ltd. v. Intas Pharms. Ltd., 14-3996 (D.N.J.) |
June 20, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Pfizer Inc. v. CFT Pharms. LLC, 14-0714 (E.D. Wis.) |
June 20, 2014 |
Hon. William E. Duffin |
Tygacil® (tigecycline injectable IV infusion) |
7,879,828 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0106 (N.D.W.V.) |
June 20, 2014 |
Hon. Irene M. Keeley |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
Biodelivery Sciences Int'l, Inc. v. RB Pharms. Ltd., IPR2014-00998 (PTAB) |
June 20, 2014 |
N/A |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832 |
Amneal Pharms., LLC v. Jazz Pharms., Inc., CBM2014-00149 (PTAB) |
June 24, 2014 |
N/A |
Xyrem® (sodium oxybate oral solution) |
7,895,059 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0820 (D. Del.) |
June 25, 2014 |
Hon. Richard G. Andrews |
Exjade® (deferasirox tablets for oral suspension) |
6,465,504 |
Shire LLC v. Ranbaxy Labs. Ltd., 14-0827 (D. Del.) |
June 25, 2014 |
Hon. Richard G. Andrews |
Intuniv® (guanfacine hydrochloride extended-release tablets) |
6,287,599 |
Orexo AB v. Actavis Elizabeth LLC, 14-0829 (D. Del.) |
June 26, 2014 |
Hon. Sue L. Robinson |
Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
8,454,996 |
Eli Lilly and Co. v. Panacea Biotec, Ltd., 14-1064 (S.D. Ind.) |
June 26, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Senju Pharm. Co., Ltd. v. Lupin, Ltd., 14-4149 (D.N.J.) |
June 26, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution) |
8,669,290 |
Novartis Pharms. Corp. v. Mylan Inc., 14-0111 (N.D.W.V.) |
June 26, 2014 |
Hon. Irene M. Keeley |
Exjade® (deferasirox tablets for oral suspension) |
6,465,504 |
Metrics, Inc. v. Senju Pharm. Co., Ltd., IPR2014-01041 (PTAB) |
June 26, 2014 |
N/A |
Prolensa® (bromfenac ophthalmic solution) |
8,129,431 |
Metrics, Inc. v. Senju Pharm. Co., Ltd., IPR2014-01043 (PTAB) |
June 26, 2014 |
N/A |
Prolensa® (bromfenac ophthalmic solution) |
8,669,290 |
Forest Labs., Inc. v. Aurobindo Pharma USA Inc., 14-0833 (D. Del.) |
June 27, 2014 |
Hon. Leonard P. Stark |
Namenda® (memantine hydrochloride tablets) |
5,061,703 |
UCB, Inc. v. Apotex Corp., 14-0834 (D. Del.) |
June 27, 2014 |
Hon. Leonard P. Stark |
Vimpat® (lacosamide oral solution) |
RE38,551 |
Par Pharm., Inc. v. Novartis Pharms. Corp., 14-0843 (D. Del.) |
June 27, 2014 |
Hon. Richard G. Andrews |
Exelon® (rivastigmine transdermal system or extended-release film) |
6,316,023 |
AstraZeneca AB v. Par Pharm., Inc., 14-0845 (D. Del.) |
June 30, 2014 |
Hon. Gregory M. Sleet |
Onglyza® (saxagliptin hydrochloride tablets) |
7,951,400 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.